Work

A Phase II Study of the MEK 1/2 Inhibitor AZD6244 (Selumetinib, ARRY-142866) in Relapsed or Refractory Multiple Myeloma

Year: 2011

Type: article

Study design: Clinical Trial

Source: Blood

DOI: 10.1182/blood.v118.21.2931.2931

Authors: Beata Holkova, Ashraf Z. Badros, Robert Geller, Peter M. Voorhees, Adriana Zingone, Neha Korde, Hui-Yi Lin, Mary Beth Tombes, Ellen Shrader, Heidi Sankala, Maciej Kmieciak, John D. Roberts, Daniel Sullivan, Ola Landgren, Steven Grant

Institutions: VCU Massey Comprehensive Cancer Center, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Billings Clinic, University of North Carolina at Chapel Hill, UNC Lineberger Comprehensive Cancer Center, National Institutes of Health, National Cancer Institute, Moffitt Cancer Center

Language: English

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2980493271

FWCI: 0.754

Cites:

Cited by: 4

Related to: 10